카이메라 테라퓨틱스(KYMR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $117.39 (+2.60%), 시가총액 $6.76B, 52주 범위 $28.14 ~ $95.03.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of
카이메라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
카이메라 테라퓨틱스의 현재 주가는 $117.39 (+2.60%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
카이메라 테라퓨틱스의 시가총액은 약 $6.76B입니다.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing